O19 Development of a paediatric brain PBPK model in children with and without meningitis

BackgroundSeveral paediatric physiologically-based pharmacokinetic (PBPK) models have been developed that incorporate developmental changes affecting plasma drug concentrations. Disposition into cerebrospinal fluid (CSF) is also age-related and influenced by physiological factors, including CSF prod...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2019-06, Vol.104 (6), p.e8-e9
Main Authors: Verscheijden, LFM, Koenderink, JB, Allegaert, K, de Wildt, SN, Russel, FGM
Format: Article
Language:English
Subjects:
Age
Antibiotics
Blood-brain barrier
Brain
Cerebrospinal fluid
Children
Flurbiprofen
Ibuprofen
Meningitis
Meropenem
Naproxen
Narcotics
Paracetamol
Pediatrics
Pharmacokinetics
Plasma
Sensitivity analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundSeveral paediatric physiologically-based pharmacokinetic (PBPK) models have been developed that incorporate developmental changes affecting plasma drug concentrations. Disposition into cerebrospinal fluid (CSF) is also age-related and influenced by physiological factors, including CSF production rate, but also by brain diseases, such as meningitis, which are associated with impaired blood-brain barrier integrity. Our aim was to develop a paediatric brain PBPK model to predict CSF drug concentrations in children with and without meningitis.MethodsA paediatric PBPK model was developed incorporating age-appropriate parameters and associated inter-individual variability. The model was validated for paracetamol, ibuprofen, flurbiprofen and naproxen, and for a paediatric meningitis population by estimating meropenem blood-brain barrier penetration using sensitivity analysis. Plasma and CSF drug concentrations derived from literature were used to perform visual predictive checks and to calculate ratios between simulated and observed AUCs in order to evaluate model performance.ResultsSimulated data were comparable to observed over a broad age range (1 day - 15 y postnatal age), for all drugs investigated. The ratios between observed and simulated AUCs were within 2-fold difference both in plasma and in CSF, indicating acceptable model performance. Disposition of meropenem into the brain was slow and CSF concentrations were lower compared to plasma concentrations. In addition, several days were needed to achieve CSF steady-state concentration.ConclusionsOur paediatric brain PBPK model provides a new tool to predict CSF concentrations in children with and without meningitis and can be used as a template model for other drugs acting in the CNS.Disclosure(s)Nothing to disclose
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2019-esdppp.19